Assessment of oral famotidine in preventing hypersensitivity reactions in patients receiving taxanes and platinum

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160310026998N13

Enrollment

360

Registered

2022-02-16

Start date

2020-11-21

Completion date

Unknown

Last updated

2022-03-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patient receiving taxanes and platinum-based anticancer agents.

Interventions

Intervention 1: Intervention group: Patients undergoing chemotherapy who received carboplatin, oxaliplatin, paclitaxel, and docetaxel received famotidine 40 mg orally (regardless of brand) before chem

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: receiving taxanes and platinum based anticancer agents

Exclusion criteria

Exclusion criteria: Having a history of drug allergies

Design outcomes

Primary

Measure	Time frame
Reduce the incidence of hypersensitivity reactions. Timepoint: Up to 2 hours after chemotherapy and 1 month later. Method of measurement: observation.	—

Secondary

Measure	Time frame
Reducing any need to reduce the dose or discontinue chemotherapy following the patient's intolerance to the hypersensitivity reaction. Timepoint: 2 hours after chemotherapy and 1 week later. Method of measurement: observation.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaba Ghaffary

Tabriz University of Medical Sciences

ghaffarys@tbzmed.ac.ir+98 33266042

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026